Yıl: 2020 Cilt: 26 Sayı: 2 Sayfa Aralığı: 112 - 121 Metin Dili: İngilizce DOI: 10.4274/tnd.2020.45467 İndeks Tarihi: 21-12-2020

Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes

Öz:
Atypical Parkinsonian syndromes include multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and dementiawith Lewy bodies (DLB). These conditions show signs of dopamine deficiency, but unlike Parkinson’s disease (PD), they do not respond to dopaminergic treatmentsand usually have a worse outcome compared with idiopathic PD. The Atypical Parkinsonian syndromes have no specific treatment or cure. Up to now, there are justa few therapeutic approaches that place emphasis on symptomatic and supportive therapies. These approaches are based on palliative care, physical or occupationaltherapy, neuropsychology, speech pathology, psychiatry, and social works. Pharmacotherapy with levodopa, dopamine agonists, amantadine, co-enzyme Q10,botulinum toxin, cholinesterase inhibitors, and selective serotonin reuptake inhibitors may improve some symptoms of PSP and CBD. In this review, we categorizesome of the recent studies on therapeutic strategies as follows: autologous transplantation of stem cells, deep transcranial magnetic stimulation, intravenousimmunoglobulin, intranasal insulin, and pimavanserin. By classifying and comparing the most recent advances in treatment strategies of the atypical parkinsoniansyndromes, we provide a benchmark for further studies to introduce new effective therapeutic methods.
Anahtar Kelime:

Atipik Parkinson Sendromları için Yeni Terapötik Stratejiler

Öz:
Atipik Parkinson sendromları arasında multisistem atrofi (MSA), progresif supranükleer palsi (PSP), kortikobazal dejenerasyon (KBD) ve Lewy cisimcikli demans bulunur (DLB). Bu hastalıklar dopamin eksikliği belirtileri gösterir, ancak Parkinson hastalığının (PH) aksine dopaminerjik tedavilere cevap vermezler ve genellikle idiyopatik PH ile karşılaştırıldığında daha kötü bir sonlanıma sahiptir. Atipik Parkinson sendromlarının spesifik bir tedavisi yoktur. Şimdiye kadar, semptomatik ve destekleyici tedavilere vurgu yapan birkaç terapötik yaklaşım vardır. Bu yaklaşımlar palyatif bakım, fiziksel veya mesleki terapi, nöropsikoloji, konuşma patolojisi, psikiyatri ve sosyal çalışmalar temellidir. Levodopa, dopamin agonistleri, amantadin, koenzim Q10, botulinum toksini, kolinesteraz inhibitörleri ve selektif serotonin geri alım inhibitörleri ile farmakoterapi, PSP ve KBD’nin bazı semptomlarını iyileştirebilir. Bu derlemede; kök hücrelerin otolog transplantasyonu, derin transkraniyal manyetik stimülasyon, intravenöz immünoglobulin, intranazal insülin ve pimavanserin gibi terapötik stratejiler üzerine yapılan son çalışmalardan bazılarını kategorize ettik. Atipik Parkinson sendromlarının tedavi stratejilerindeki en son gelişmelerin sınıflandırılması ve karşılaştırılması; yeni ve etkili terapötik yöntemlerin geliştirilmesi için yapılacak ileri çalışmalara kriter sağlar.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Williams DR, Lees AJ. How do patients with Parkinsonism present? A clinicopathological Study. Intern Med J 2009;39:7-12.
  • 2. Jankovic J. Parkinson disease and other movement disorder. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Neurology in clinical practice. 7th edition. Philadelphia: Elsevier 2016:1422-1460.
  • 3. Dickson DW. Parkinson's disease and Parkinsonism: Neuropathology. Cold Spring Harb Perspect Med 2012;2a009258.
  • 4. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary Parkinsonism. Mov Disord 2011;26:1083-1095.
  • 5. Nath U, Ben-Shlomo Y, Thomson R, Lees A, Burn DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003;2:910-916.
  • 6. David RW, Rohan de S, Dominic P, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain 2005;128:1247-1258.
  • 7. Eggert K, Oertel W, Reichmann H, et al. Leitlinien für Diagnostik und Therapie inder Neurologie.Parkinson-Syndrome. Deutsche Gesellschaft für Neurologie 2012;2:1-77.
  • 8. Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010;133:1578-1590.
  • 9. Moretti DV, Binetti G, Zanetti O, Frisoni GB. Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy. Neuropsychiatr Dis Treat 2014;10:1003-1009.
  • 10. Amie H, Charles M, Jennifer N, Joseph Q. The Effects of Amantadine on the Progression of Progressive Supranuclear Palsy (PSP). Neurology 2018;90 (15 Suppl):P6.068.
  • 11. Dash SK. Zolpidem in Progressive Supranuclear Palsy. Case Rep Neurol Med 2013;2013:250865.
  • 12. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270-279.
  • 13. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42-80.
  • 14. Stamelou M, Höglinger G. A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs 2016;30:629-636.
  • 15. Levin J, Kurz A, Arzberger T, Giese A, Höglinger GU. The Differential Diagnosis and Treatmentof Atypical Parkinsonism. Dtsch Arztebl Int 2016;113:61-69.
  • 16. Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985;35:1189-1193.
  • 17. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 1993;16:338-346.
  • 18. Stamelou M, Bhatia K. Atypical Parkinsonism:diagnosis and treatment. Neurol Clin 2015;33:39-56.
  • 19. Min S, Cho S, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010;67:853-866.
  • 20. Stamelou M, Adam L Boxer AL. Disease-Modifying Treatments for Progressive Supranuclear Palsy. Mov Disord Clin Pract 2015;2:3-5.
  • 21. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black R. Progress in the active Immunotherapeutic approach to Alzheimer's disease: clinical investigation into AN1792 associated meningoencephalitis. Neurodegener Dis 2008;5:194-196.
  • 22. Adam B, Anthony L, Murray G. Davunetide for Progressive Supranuclear Palsy: a multicenter, randomized, double-blind, placebo controlled trial. Lancet Neurol 2014;13:676-685.
  • 23. DeVos S, Goncharoff D, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci 2013;33:12887-12897.
  • 24. Swerdlow R, Golbe L, Parks J, et al. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J Neurochem 2000;75:1681-1684.
  • 25. Albers D, Swerdlow R, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol 2001;168:196- 198.
  • 26. Giulio MP, Hanna KR, Ismael SM, Jun W, Lap H. Development of a grape seed polyphenolic extract with antioligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies. J Neurochem 2010;114:1557-1568.
  • 27. Choi SW, Park KB, Woo SK, Kang SK, Ra JC. Treatment of progressive supranuclear palsy with autologous adipose tissue-derived mesenchymal stem cells: a case report. J Med Case Rep 2014;8:87.
  • 28. Pallanti S, Marras A. Transcranial Magnetic Stimulation Treatment for Motor Symptoms in Parkinson’s disease: A Review of Two Decades of Studies. Alzheimers Disease Parkinsonism 2015;5:191.
  • 29. Richard MT, Adam LB. Clinical Trials: past, current and future for atypical parkinsonian syndromes. Semin Neurol 2014;34:225-234.
  • 30. Dickson D, Bergeron C, Chin S, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-946.
  • 31. Shih L, Tarsy D. Deep brain stimulation for the treatment of atypical Parkinsonism. Mov Disord 2007;22:2149-2155.
  • 32. Ling H, O'Sullivan S, Holton J, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010;133:2045-2057.
  • 33. Armstrong MJ. Diagnosis and treatment of corticobasal degeneration. Curr Treat Options Neurol 2014;16:282.
  • 34. Mario F, Jill S, Aaron M, Eliot L. Preliminary Findings: Behavioral Worsening on Donepezil in Patients with Frontotemporal Dementia. The American Journal of Geriatric Psychiatry 2007;15:84-87.
  • 35. Kertesz A, Morlog D, Mervin B, et al. Galantamine in Frontotemporal Dementia and Primary Progressive Aphasia. Dementia and Geriatric Cognitive Disorders 2008;25:178-185.
  • 36. Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, doubleblind, placebo-controlled trial. Lancet Neurol 2013;12:149-156.
  • 37. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(Suppl 3):42-80.
  • 38. Herrmann N, Black S, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 2012;20:789-797.
  • 39. Bruns MB, Josephs KA. Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy. Int Rev Psychiatry 2013;25:197- 209.
  • 40. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomized controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355-359.
  • 41. Martinon-Torres G, Fioravanti M, Grimley E. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004;4:CD004990.
  • 42. Wenning G, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000;68:434-440.
  • 43. Stefanova N, Bücke P, Duerr S, Wenning G. Multiple system atrophy: an update. Lancet Neurol 2009;8:1172-1178.
  • 44. Wenning G, Colosimo C, Geser C, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
  • 45. Schrag A, Ben-Shlomo Y, Quinn N. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771-1775.
  • 46. Jecmenica-Lukic M, Poewe W, Tolosa E, Wenning G. Premotor signs and symptoms of multiple system atrophy. Lancet Neurol 2012;11:361-368.
  • 47. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with Parkinsonism: a review of the literature. Mov Disord 2007;22:2141- 2148.
  • 48. Wenning G, Ben-Shlomo Y, Hughes A, Daniel S, Lees A, Quinn N. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson’s disease?. J Neurol Neurosurg Psychiatry 2000;68:434-440.
  • 49. Wenning G. Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy. Clin Neuropharmacol 2005;28:225-227.
  • 50. Von Lewinski F, Schwan M, Paulus W, Trenkwalder C, Sommer M. Impairment of brainstem implicit learning paradigms differentiates multiple system atrophy (MSA) from idiopathic Parkinson syndrome. BMJ Open 2013;3:e003098.
  • 51. Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord 2006;12:432-437.
  • 52. Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord 2010;3:249- 263.
  • 53. Rohrer G, Höglinger GU, Levin J. Symptomatic therapy of multiple system atrophy. Auton Neurosci 2018;211:26-30.
  • 54. Heo JH, Lee ST, Chu K, Kim M. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 2008;271:87-90.
  • 55. Gazulla J, Benavente M. Improvements in the symptoms of olivopontocerebellar atrophy with gabapentin. Rev Neurol 2008;40:285- 288.
  • 56. Sun Z, Jia D, Shi Y, et al. Prediction of orthostatic hypotension in multiple system atrophy and Parkinson disease. Sci Rep 2016;6:21649.
  • 57. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008;358:615-624.
  • 58. Singer W, Sandroni P, Opfer-Gehrking T, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006; 63:513- 518.
  • 59. Kaufmann H. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res 2008;18(Suppl 1):19-24.
  • 60. Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N. Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol 2017;14:79-89.
  • 61. Papatsoris A, Papapetropoulos S, Singer C, Deliveliotis C. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn 2008;27:22-27.
  • 62. Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816-823.
  • 63. Sakakibara R, Matsuda S, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Re 2003;13:106-108.
  • 64. Papatsoris A, Papapetropoulos S, Singer C, Deliveliotis C. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn 2008;27:22-27.
  • 65. Hussain I, Brady C, Swinn M, Mathias C, Fowler C. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-374.
  • 66. Papapetropoulos S, Tuchman A, Sengun C, Russell A, Mitsi G, Singer C. Anterocollis: clinical features and treatment options. Med Sci Monit 2008;14:CR427-CR430.
  • 67. Takei A, Hamada S, Homma S, Hamada K, Tashiro K, Hamada T. Amelioration of subacute camptocormia in multiple system atrophy by protirelin tartrate. Mov Disord 2009;24:2022-2023.
  • 68. Vetrugno R, Liguori R, Cortelli P, et al. Sleep-related stridor due to dystonic vocal cord motion and neurogenic tachypnea/tachycardia in multiple system atrophy. Mov Disord 2007;22:673-678.
  • 69. Ghorayeb I, Bioulac B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm 2005;112:1669-1675.
  • 70. Anderson K, Shneerson J. Drug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepam. J Clin Sleep Med 2009;5:235-239.
  • 71. Ringman J, Simmons J. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55:870-871.
  • 72. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003;4:281-284.
  • 73. Lisa M Benrud-Larson LM, Paola Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. Move Dis 2005;20:951-957.
  • 74. Valera E, Monzio Compagnoni G, Masliah E. Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopath. Neuropathol Appl Neurobiol 2016;42:95-106.
  • 75. Fonseca-Ornelas L, Eisbach S, Paulat M, et al. Small molecule-mediated stabilization of vesicle associated helical alpha-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun 2014;5:5857.
  • 76. Kiely AP, Miners JS, Courtney R, Strand C, Love S, Holton JL. Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of α-synuclein in multiple system atrophy. Neuropathol Appl Neurobiol 2019;45:347-360.
  • 77. Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol 2012;12:131.
  • 78. Mandler M, Valera E, Rockenstein E, et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Neurodegener 2015;10:10.
  • 79. Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mousemodel of multiple system atrophy. Glia 2014;62:317-337.
  • 80. Sandy S, Bryce V. New hope for devastating neurodegenerative disease. Brain 2017;140:1177-1179.
  • 81. Phil H, Hyun P. Bone Marrow-Derived Mesenchymal Stem Cell Therapy as a Candidate Disease-Modifying Strategy in Parkinson’s Disease and Multiple System Atrophy. J Clin Neurol 2009;5:1-10.
  • 82. Diguet E, Fernagut P, Scherfler C, Wenning G, Tison F. Effects of riluzole on combined MPTP 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice. J Neural Transm 2005;112:613-631.
  • 83. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh P. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009;132:156-171.
  • 84. Holmberg B, Johansson JO, Poewe W, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebocontrolled study. Mov Disord 2007;22:113811-113844.
  • 85. Heo J, Lee S, Chu K, Kim M. The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy. J Neurol Sci 2008; 271:87-90.
  • 86. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther 2013;138:155-175.
  • 87. Sutherland G, Halliday G, Silburn P, et al. Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord 2009;24:833-838.
  • 88. Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013;369:233- 244.
  • 89. Sung J, Park S, Lee C, et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem 2005;280:25216-25224.
  • 90. McKeith I, Dickson D, Lowe J, et al; Consortium on DLB: Diagnosis and management of dementia with Lewy bodies: third report of the DLK Consortium. Neurology 2005;65:1863-1872.
  • 91. Boot BP, McDade EM, McGinnis SM, Boeve BF. Treatment of Dementia with Lewy Bodies. Curr Treat Options Neurol 2013;15:738-764.
  • 92. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2013;3:CD006504.
  • 93. Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci 2006;60:190-195.
  • 94. Matsunaga S, Kishi T, Yasue I, Iwata N. Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. Int J Neuropsychopharmacol 2015;19:pyv086.
  • 95. Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther 2015;7:45.
  • 96. Vann Jones S, O'Brien J. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014;44:673-683.
  • 97. Hebron ML, Lonskaya I, E-H Moussa C. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alphasynuclein in Parkinson’s disease models. Hum Mol Genet 2013;22:3315- 3328.
  • 98. Veronica Lindström V, Ihse E, Fagerqvist T, et al. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson’s disease and other Lewy body disorders. Immunotherapy 2014;6:141-153.
  • 99. Masliah E, Rockenstein E, Mante M, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011;6:e19338.
  • 100. Mandler M, Valera E, Rockenstein E, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 2014;127:861-879.
  • 101. McCormack A, Mak S, Henderson J, Bumcrot D, Farrer M, Di Monte D. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 2010;5:e12122.
  • 102. Qiang Z, Young-cho K, Nandakumar S. Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci 2015;9:293.
APA Maghbooli M, mohammadzadeh V, yousefi m (2020). Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. , 112 - 121. 10.4274/tnd.2020.45467
Chicago Maghbooli Mehdi,mohammadzadeh Vida,yousefi mehran Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. (2020): 112 - 121. 10.4274/tnd.2020.45467
MLA Maghbooli Mehdi,mohammadzadeh Vida,yousefi mehran Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. , 2020, ss.112 - 121. 10.4274/tnd.2020.45467
AMA Maghbooli M,mohammadzadeh V,yousefi m Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. . 2020; 112 - 121. 10.4274/tnd.2020.45467
Vancouver Maghbooli M,mohammadzadeh V,yousefi m Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. . 2020; 112 - 121. 10.4274/tnd.2020.45467
IEEE Maghbooli M,mohammadzadeh V,yousefi m "Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes." , ss.112 - 121, 2020. 10.4274/tnd.2020.45467
ISNAD Maghbooli, Mehdi vd. "Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes". (2020), 112-121. https://doi.org/10.4274/tnd.2020.45467
APA Maghbooli M, mohammadzadeh V, yousefi m (2020). Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. Türk Nöroloji Dergisi, 26(2), 112 - 121. 10.4274/tnd.2020.45467
Chicago Maghbooli Mehdi,mohammadzadeh Vida,yousefi mehran Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. Türk Nöroloji Dergisi 26, no.2 (2020): 112 - 121. 10.4274/tnd.2020.45467
MLA Maghbooli Mehdi,mohammadzadeh Vida,yousefi mehran Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. Türk Nöroloji Dergisi, vol.26, no.2, 2020, ss.112 - 121. 10.4274/tnd.2020.45467
AMA Maghbooli M,mohammadzadeh V,yousefi m Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. Türk Nöroloji Dergisi. 2020; 26(2): 112 - 121. 10.4274/tnd.2020.45467
Vancouver Maghbooli M,mohammadzadeh V,yousefi m Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes. Türk Nöroloji Dergisi. 2020; 26(2): 112 - 121. 10.4274/tnd.2020.45467
IEEE Maghbooli M,mohammadzadeh V,yousefi m "Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes." Türk Nöroloji Dergisi, 26, ss.112 - 121, 2020. 10.4274/tnd.2020.45467
ISNAD Maghbooli, Mehdi vd. "Update on Therapeutic Strategies for Atypical Parkinsonian Syndromes". Türk Nöroloji Dergisi 26/2 (2020), 112-121. https://doi.org/10.4274/tnd.2020.45467